Associations between lifetime classic psychedelic use and cardiometabolic diseases

Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychede...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Otto Simonsson, Walter Osika, Robin Carhart-Harris, Peter S. Hendricks
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da2659
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1bec952e2b6e4e63b6ebf6dd00da2659
record_format dspace
spelling oai:doaj.org-article:1bec952e2b6e4e63b6ebf6dd00da26592021-12-02T15:33:13ZAssociations between lifetime classic psychedelic use and cardiometabolic diseases10.1038/s41598-021-93787-42045-2322https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da26592021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93787-4https://doaj.org/toc/2045-2322Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.Otto SimonssonWalter OsikaRobin Carhart-HarrisPeter S. HendricksNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-5 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Otto Simonsson
Walter Osika
Robin Carhart-Harris
Peter S. Hendricks
Associations between lifetime classic psychedelic use and cardiometabolic diseases
description Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.
format article
author Otto Simonsson
Walter Osika
Robin Carhart-Harris
Peter S. Hendricks
author_facet Otto Simonsson
Walter Osika
Robin Carhart-Harris
Peter S. Hendricks
author_sort Otto Simonsson
title Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_short Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_full Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_fullStr Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_full_unstemmed Associations between lifetime classic psychedelic use and cardiometabolic diseases
title_sort associations between lifetime classic psychedelic use and cardiometabolic diseases
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da2659
work_keys_str_mv AT ottosimonsson associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases
AT walterosika associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases
AT robincarhartharris associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases
AT petershendricks associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases
_version_ 1718387068170665984